Characteristics of Opsoclonus-Myoclonus Syndrome in Patients of the Largest Pediatric Hospital in Latin America

• Published in: Pediatric neurology Vol. 154; pp. 9 - 14
• Main Authors: Zeny, Michelle Silva, do Valle, Daniel Almeida, Santos, Mara Lúcia Schmitz Ferreira, Bara, Tiago S., Cordeiro, Mara L.
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.05.2024
• Subjects: Brazil; Child; Children; Cyclophosphamide; Hospitals, Pediatric; Humans; Immunosuppressive Agents; Kinsbourne syndrome; Latin America; Opsoclonus-myoclonus syndrome; Opsoclonus-Myoclonus Syndrome - diagnosis; Opsoclonus-Myoclonus Syndrome - drug therapy; Opsoclonus-Myoclonus Syndrome - etiology; Paraneoplastic; Latin America; Brazil; Kinsbourne syndrome; Paraneoplastic; Children; Opsoclonus-myoclonus syndrome; Latin America
• ISSN: 0887-8994; 1873-5150
• DOI: 10.1016/j.pediatrneurol.2023.12.028

Opsoclonus-myoclonus syndrome (OMS) is a rare neuroinflammatory disorder characterized by ataxia, opsoclonus, and myoclonus. Clinical diagnosis of OMS has been challenging; therefore, we sought to determine the clinical and treatment profiles of patients with OMS at the largest pediatric hospital in Latin America. We analyzed the data of patients diagnosed with OMS between 2010 and 2020 at Pequeno Principe Hospital (Brazil) to determine the corresponding clinical profile more accurately. Of the approximately 50,000 visitors to our pediatric neurology department from 2010 to 2020, 10 patients with OMS were observed. Five nontumor cases included three parainfectious and two idiopathic cases. The median time from symptom onset to diagnosis was 34 days. All patients with diagnostic OMS criteria in the idiopathic, nontumor group underwent whole-exome sequencing, with potentially pathogenic mutations identified in two cases. Nine patients were treated with methylprednisolone pulse, followed by oral steroids; eight received one or more intravenous immunoglobulin treatments; and six received azathioprine and cyclophosphamide. Complete symptomatic recovery was observed in only one patient. OMS diagnosis remains challenging. Diagnostic suspicion is necessary to improve the management of these patients and allow early immunosuppressive treatment. Paraneoplastic etiology is the most prevalent. In idiopathic patients who do not respond to immunosuppressive treatment, tests, such as whole-exome sequencing, may reveal a differential diagnosis. Genetic alterations that increase the risk of tumors may be an important clue to the pathophysiology of OMS.